Neurological Sciences

, Volume 39, Issue 4, pp 733–739 | Cite as

Real life evaluation of safinamide effectiveness in Parkinson’s disease

  • Francesca Mancini
  • Alessio Di Fonzo
  • Giulia Lazzeri
  • Linda Borellini
  • Vincenzo Silani
  • Marco Lacerenza
  • Cristoforo Comi
Original Article
  • 170 Downloads

Abstract

In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.

Keywords

Parkinson’s disease Motor fluctuations Dyskinesias Safinamide 

Notes

Acknowledgements

We thank Maggie Dufresne for the linguistic revision of the text and the patients and their caregivers for the collaboration.

Compliance with ethical standards

Conflict of interests

Francesca Mancini has received speaker honoraria from Zambon and Abbvie.

Alessio Di Fonzo has received a speaker honorarium from Sanofi Genzyme.

Giulia Lazzeri has no conflict of interest.

Linda Borellini has no conflict of interest.

Vincenzo Silani serves on the Board of Cytokinetics for the Vitality trial in ALS and he received consulting fees.

Marco Lacerenza has received speaker honoraria from Mundipharma.

Cristoforo Comi has received financial support (including research funding and speaker honoraria) from Lundbeck, Chiesi, UCB, Zambon, and Abbvie.

Authorship

All authors have participated in the research and/or article preparation.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54(11 Suppl. 5):S21–S23PubMedGoogle Scholar
  2. 2.
    Rajput AH, Birdi S (1997) Epidemiology of Parkinson’s disease. Parkinsonism Relat Disord 3(4):175–186.  https://doi.org/10.1016/S1353-8020(97)00029-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study. Brain 123(Pt 11):2297–2305.  https://doi.org/10.1093/brain/123.11.2297 CrossRefPubMedGoogle Scholar
  4. 4.
    Za’dori D, Szala’rdy L, Toldi J et al (2013) Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease. J Neural Transm 120:673–681CrossRefGoogle Scholar
  5. 5.
    Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(10):2731–2742.  https://doi.org/10.1093/brain/awu195 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pevarello P, Traquandi G, Bonsignori A, McArthur RA, Maj R, Caccia C, Salvati P, Varasi M (1999) Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety. Bioorg Med Chem Lett 9(13):1783–1788.  https://doi.org/10.1016/S0960-894X(99)00271-1 CrossRefPubMedGoogle Scholar
  7. 7.
    Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L, Mazzanti M, Mancinelli E, Varasi M, Fariello RG (1999) Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 288(3):1151–1159PubMedGoogle Scholar
  8. 8.
    Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 10;67(7 Suppl 2):S18–S23CrossRefGoogle Scholar
  9. 9.
    Binda C, Milczek EM, Bonivento D, Wang J, Mattevi A, Edmondson DE (2011) Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Curr Top Med Chem 11(22):2788–2796.  https://doi.org/10.2174/156802611798184355 CrossRefPubMedGoogle Scholar
  10. 10.
    Olanow CW, Stocchi F (2016) Safinamide—a new therapeutic option to address motor symptoms and motor complications in mid-to-late stage Parkinson’s disease. Eur Neurol Rev 11(Suppl 2):2–15Google Scholar
  11. 11.
    Cattaneo C, Ferla RL, Bonizzoni E, Sardina M (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis 5(3):475–481.  https://doi.org/10.3233/JPD-150569 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Onofrj M, Bonanni L, Thomas A (2008) An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 17(7):1115–1125.  https://doi.org/10.1517/13543784.17.7.1115 CrossRefPubMedGoogle Scholar
  13. 13.
    Stocchi F, Torti M (2016) Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide. Drug Des Devel Ther 10:609–618.  https://doi.org/10.2147/DDDT.S77749 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. A randomized clinical trial. JAMA Neurol 74(2):216–224.  https://doi.org/10.1001/jamaneurol.2016.4467 CrossRefPubMedGoogle Scholar
  15. 15.
    Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 29(2):229–237.  https://doi.org/10.1002/mds.25751 CrossRefPubMedGoogle Scholar
  16. 16.
    Deeks ED (2015) Safinamide: first global approval. Drugs 75(6):705–711.  https://doi.org/10.1007/s40265-015-0389-7 CrossRefPubMedGoogle Scholar
  17. 17.
    Baker DE, Kim AP (2017) Safinamide. Hosp Pharm 52(8):532–543.  https://doi.org/10.1177/0018578717726046 CrossRefPubMedGoogle Scholar
  18. 18.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184.  https://doi.org/10.1136/jnnp.55.3.181 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Goetz CG, Nutt JG, Stebbins GT (2008) The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 23(16):2398–2403.  https://doi.org/10.1002/mds.22341 CrossRefPubMedGoogle Scholar
  20. 20.
    Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653.  https://doi.org/10.1002/mds.23429 CrossRefPubMedGoogle Scholar
  21. 21.
    Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500–506.  https://doi.org/10.1038/sj.bjp.0703826 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neurology–Stroke Unit and Laboratory of NeuroscienceIRCCS Istituto Auxologico ItalianoMilanItaly
  2. 2.Neurology Unit, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, “Dino Ferrari” Center, Neuroscience Section, Department of Pathophysiology and TransplantationUniversità Degli Studi di MilanoMilanItaly
  3. 3.Neuropathophysiology Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore PoliclinicoUniversità degli Studi di MilanoMilanItaly
  4. 4.Department of Neurology-Stroke Unit and Laboratory of Neuroscience, “Dino Ferrari” Centre - Centre for Neurotechnology and Brain Therapeutics, Department of Pathophysiology and TransplantationUniversità degli Studi di MilanoMilanItaly
  5. 5.Neurology ServiceCasa di Cura Humanitas San Pio XMilanItaly
  6. 6.Department of Translational MedicineUniversity of Piemonte OrientaleNovaraItaly

Personalised recommendations